Usefulness of a New Therapy Using Rebamipide Eyedrops in Patients with VKC/AKC Refractory to Conventional Anti-Allergic Treatments
Background: Rebamipide, a gastroprotective drug, has been reported to suppress gastric mucosal inflammation. In Japan, rebamipide eyedrops have recently been approved for the treatment of dry eye disease. Some patients with allergic conjunctival diseases such as vernal keratoconjunctivitis (VKC) or...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2014-01-01
|
| Series: | Allergology International |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S1323893015300113 |
| _version_ | 1828178525557882880 |
|---|---|
| author | Mayumi Ueta Chie Sotozono Ayaka Koga Norihiko Yokoi Shigeru Kinoshita |
| author_facet | Mayumi Ueta Chie Sotozono Ayaka Koga Norihiko Yokoi Shigeru Kinoshita |
| author_sort | Mayumi Ueta |
| collection | DOAJ |
| description | Background: Rebamipide, a gastroprotective drug, has been reported to suppress gastric mucosal inflammation. In Japan, rebamipide eyedrops have recently been approved for the treatment of dry eye disease. Some patients with allergic conjunctival diseases such as vernal keratoconjunctivitis (VKC) or atopic keratoconjunctivitis (AKC) manifest dry eye with decreased tear break-up time only. We report patients with VKC/AKC refractory to anti-allergic treatments who responded to the combination of rebamipide eyedrops and conventional anti-allergic treatments with anti-allergic- and/or immunosuppressive/steroid eyedrops.
Methods: Four patients with allergic conjunctival diseases with giant papillae (VKC or AKC) instilled rebamipide eyedrops three or four times a day for varying periods. All had dry eye with decreased tear break-up time. We evaluated changes in the size of their giant papillae using Image J software.
Results: We observed attenuation of the giant papillae in all 4 patients. In 2 patients with severe disease, whose giant papillae had become larger despite the administration of tacrolimus and steroids, the addition of rebamipide contributed to their attenuation. In 2 patients with mild disease, the giant papillae had become larger or remained the same size despite the administration of anti-allergy drugs; the addition of rebamipide eyedrops also resulted in the attenuation of their giant papillae.
Conclusions: Our findings suggest that rebamipide eyedrops might attenuate giant papillae in patients with allergic conjunctival diseases and that these eyedrops may be useful for the treatment of not only dry eye but also of allergic conjunctival diseases. |
| first_indexed | 2024-04-12T05:17:23Z |
| format | Article |
| id | doaj.art-ce0ec8210d0747cda1b956a2e6cc0b59 |
| institution | Directory Open Access Journal |
| issn | 1323-8930 |
| language | English |
| last_indexed | 2024-04-12T05:17:23Z |
| publishDate | 2014-01-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Allergology International |
| spelling | doaj.art-ce0ec8210d0747cda1b956a2e6cc0b592022-12-22T03:46:36ZengElsevierAllergology International1323-89302014-01-01631758110.2332/allergolint.13-OA-0605Usefulness of a New Therapy Using Rebamipide Eyedrops in Patients with VKC/AKC Refractory to Conventional Anti-Allergic TreatmentsMayumi Ueta0Chie Sotozono1Ayaka Koga2Norihiko Yokoi3Shigeru Kinoshita4Department of Ophthalmology, Kyoto Prefectural University of Medicine, Hirokoji, Kawaramachi, Kamigyo-ku, Kyoto 602–0841, Japan.Department of Ophthalmology, Kyoto Prefectural University of Medicine, Hirokoji, Kawaramachi, Kamigyo-ku, Kyoto 602–0841, Japan.Department of Ophthalmology, Kyoto Prefectural University of Medicine, Hirokoji, Kawaramachi, Kamigyo-ku, Kyoto 602–0841, Japan.Department of Ophthalmology, Kyoto Prefectural University of Medicine, Hirokoji, Kawaramachi, Kamigyo-ku, Kyoto 602–0841, Japan.Department of Ophthalmology, Kyoto Prefectural University of Medicine, Hirokoji, Kawaramachi, Kamigyo-ku, Kyoto 602–0841, Japan.Background: Rebamipide, a gastroprotective drug, has been reported to suppress gastric mucosal inflammation. In Japan, rebamipide eyedrops have recently been approved for the treatment of dry eye disease. Some patients with allergic conjunctival diseases such as vernal keratoconjunctivitis (VKC) or atopic keratoconjunctivitis (AKC) manifest dry eye with decreased tear break-up time only. We report patients with VKC/AKC refractory to anti-allergic treatments who responded to the combination of rebamipide eyedrops and conventional anti-allergic treatments with anti-allergic- and/or immunosuppressive/steroid eyedrops. Methods: Four patients with allergic conjunctival diseases with giant papillae (VKC or AKC) instilled rebamipide eyedrops three or four times a day for varying periods. All had dry eye with decreased tear break-up time. We evaluated changes in the size of their giant papillae using Image J software. Results: We observed attenuation of the giant papillae in all 4 patients. In 2 patients with severe disease, whose giant papillae had become larger despite the administration of tacrolimus and steroids, the addition of rebamipide contributed to their attenuation. In 2 patients with mild disease, the giant papillae had become larger or remained the same size despite the administration of anti-allergy drugs; the addition of rebamipide eyedrops also resulted in the attenuation of their giant papillae. Conclusions: Our findings suggest that rebamipide eyedrops might attenuate giant papillae in patients with allergic conjunctival diseases and that these eyedrops may be useful for the treatment of not only dry eye but also of allergic conjunctival diseases.http://www.sciencedirect.com/science/article/pii/S1323893015300113allergic conjunctivitisatopydry eye with decreased tear break-up timegiant papillarebamipide |
| spellingShingle | Mayumi Ueta Chie Sotozono Ayaka Koga Norihiko Yokoi Shigeru Kinoshita Usefulness of a New Therapy Using Rebamipide Eyedrops in Patients with VKC/AKC Refractory to Conventional Anti-Allergic Treatments Allergology International allergic conjunctivitis atopy dry eye with decreased tear break-up time giant papilla rebamipide |
| title | Usefulness of a New Therapy Using Rebamipide Eyedrops in Patients with VKC/AKC Refractory to Conventional Anti-Allergic Treatments |
| title_full | Usefulness of a New Therapy Using Rebamipide Eyedrops in Patients with VKC/AKC Refractory to Conventional Anti-Allergic Treatments |
| title_fullStr | Usefulness of a New Therapy Using Rebamipide Eyedrops in Patients with VKC/AKC Refractory to Conventional Anti-Allergic Treatments |
| title_full_unstemmed | Usefulness of a New Therapy Using Rebamipide Eyedrops in Patients with VKC/AKC Refractory to Conventional Anti-Allergic Treatments |
| title_short | Usefulness of a New Therapy Using Rebamipide Eyedrops in Patients with VKC/AKC Refractory to Conventional Anti-Allergic Treatments |
| title_sort | usefulness of a new therapy using rebamipide eyedrops in patients with vkc akc refractory to conventional anti allergic treatments |
| topic | allergic conjunctivitis atopy dry eye with decreased tear break-up time giant papilla rebamipide |
| url | http://www.sciencedirect.com/science/article/pii/S1323893015300113 |
| work_keys_str_mv | AT mayumiueta usefulnessofanewtherapyusingrebamipideeyedropsinpatientswithvkcakcrefractorytoconventionalantiallergictreatments AT chiesotozono usefulnessofanewtherapyusingrebamipideeyedropsinpatientswithvkcakcrefractorytoconventionalantiallergictreatments AT ayakakoga usefulnessofanewtherapyusingrebamipideeyedropsinpatientswithvkcakcrefractorytoconventionalantiallergictreatments AT norihikoyokoi usefulnessofanewtherapyusingrebamipideeyedropsinpatientswithvkcakcrefractorytoconventionalantiallergictreatments AT shigerukinoshita usefulnessofanewtherapyusingrebamipideeyedropsinpatientswithvkcakcrefractorytoconventionalantiallergictreatments |